D ecision makers require predictions of costeffectiveness over a time horizon that is sufficient to capture material differences in costs and health outcomes across relevant comparators. The ideal Randomized Controlled Trial (RCT) for costeffectiveness analysis (CEA) would: include all relevant comparators, produce unbiased precise estimates when analyzed as randomized, and measure all endpoints relevant to the decision over a sufficient time horizon. Such trials are rare. To fill this gap, decision analytical models are developed to synthesize the available evidence in an attempt to recreate an ''ideal trial''. Decision models that include ''time to event'' endpoints typically need to extrapolate beyond the observed data to account for censoring.
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The method(s) chosen for extrapolation should minimize bias and maximize precision. However, in practice, it is challenging to assess and balance these criteria. It has been recognized that we are unlikely to obtain the best estimates simply by closer scrutiny of data from individual trials. Rather, we need to select methods that make use of the available evidence in its entirety, including trial and observational data and expert opinion. The methods chosen should also be transparent and facilitate sensitivity analysis. This allows decision makers to judge whether additional evidence is required, and to substitute their own judgements regarding uncertain parameters. This laudable goal raises important research questions regarding the appropriate selection of methods for synthesis and temporal extrapolation.
The 8 papers published in this special issue highlight recent progress in methods for extrapolation in CEA. Several of these papers discuss different aspects of evidence synthesis. Guyot and others harness Bayesian multi-parameter evidence synthesis to combine evidence from 4 sources: an RCT, general population database, cancer registry and expert opinion. 1 Negrín and others argue in favor of Bayesian model averaging as a principled approach for weighting alternative parametric extrapolations. 2 The methodological review by Jackson and others defines the assumptions made by approaches for incorporating external data. 3 The authors also promote a future research agenda for developing methods to formally eliciting expert opinion for extrapolation methods. Hoogenveen and others present a mathematical modelling approach for predicting the effects of interventions on mortality across multiple disease areas. 4 Lousdal and others advocate an approach for estimating mean survival times when only published estimates of median survival are available. 5 Meacock and others consider some of the issues that may arise when attempting to extrapolate survival in the broader setting of health policy evaluations. 6 The papers by Williams and others discuss the relative merits of extrapolation models with alternative structures, namely partitioned survival models (PSMs) and state transition models (STMs); for example multi-state and Markov models. 7, 8 In the case study by Williams and others, the estimates of the Incremental Cost-Effectiveness Ratios (ICERs) range from £13,000 to £29,000 per QALY, according to precisely which method is chosen. 7 Clearly, the choice of which model structure to use for extrapolation could be an important factor in the ultimate treatment recommendation. 9 In PSMs, the relationship between treatment and each time to event endpoint, for example progression or death, is estimated independently. In this form of modelling, the cumulative probabilities of experiencing an event are estimated directly as a function of time -transitions between states are not explicitly modelled. By contrast, in STMs, transitions between states are explicitly modelled. Compared to PSMs, STMs are more complex in both implementation and estimation of model parameters. That said, the tutorial paper by Williams and others should help analysts armed with requisite Individual Patient Data (IPD) to implement even the more complex forms of STM, such as multi-state models. 8 We believe that an appreciation of the underlying causal relationships is pivotal when selecting an appropriate approach. We illustrate the causal frameworks for these 2 approaches in Figure 1 . Although these diagrams appear simple, the underlying causal assumptions are not.
In PSMs, the causal relationships between endogenous variables are not explicitly modelled. Endogenous variables are those that are estimated within the model, such as time to progression and time to death. An example of a causal relationship between endogenous variables is the relationship between the time to progression, and the subsequent time to death. A natural consequence of keeping these relationships implicit is that this limits the scope for sensitivity analyses concerning the underlying causal assumptions. For example, it is difficult to make alternative assumptions about the effect of treatment cessation on outcomes, such as no, or tapering, additional effect beyond the end of treatment. When developing PSMs, it is essential to consider the underlying assumptions about the causal relationships between endogenous variables. By contrast, in STMs, the causal relationships between endogenous variables are explicitly modelled. This facilitates sensitivity analyses related to these causal relationships and allows inclusion of external evidence on specific causal relationships.
Both model structures face important concerns regarding the potential for bias if the underlying causal assumptions are not met. With PSMs, a concern is that the extrapolation of overall survival typically does not account for the effects of changes in endogenous variables, such as progression or treatment status. Despite this omission, censoring is still treated as uninformative. With STMs, the outstanding concern is that the estimation of post-randomization causal relationships between endogenous variables, such as time to progression and subsequent survival time, may be subject to omitted variable bias. For example, if the model estimates the time to death post-progression but ignores the causal effect of time to progression on subsequent survival time, the model will provide biased estimates of effectiveness and cost-effectiveness.
The chosen approach should make the best use of the available data, and allow decision makers to understand and explore uncertainties about these fundamental causal relationships. STMs are attractive in allowing a wider synthesis of data and more extensive sensitivity analysis compared to PSM. However, we should not underestimate the challenge For either PSM or STM, there is a strong argument for considering the effects of endogenous variables, perhaps by incorporating time-varying variables in the survival modelling. Whichever method is chosen, access to IPD and careful consideration of causal assumptions is essential to improve the quality of CEA and subsequent decisions about the choice of health care technologies and services. The stakes are high; as regulatory and government agencies move to ever faster access to new technologies specific to the individual patient's prognosis, there will be increased pressure to develop approaches that make the best use of available evidence when predicting the effects of alternative interventions on patients' long-term health.
